What is a surgical robot?

What surgical robotics is, what it isn't

A surgical robot is a computer-assisted operative platform that interposes robotic arms, instruments, and visualization systems between the surgeon and the patient. The category sits adjacent to the broader physical AI cohort and the AMR / industrial robotics lineup, but the regulatory framework, customer base (hospital systems and surgical-services networks), and verification discipline are distinct.

Per DEPLOY's framework, the editorial throughline for the surgical robotics cohort is FDA clearance as the verified gating event. Demos, prototypes, and corporate-scale parentage do not substitute for the cleared-to-market regulatory milestone. The framework reads pre-clearance entries at research tier regardless of investment size, lab demonstrations, or marketing claims; cleared entries surface at the verification depth their installed base and clearance scope support.

---

The 2026 commercial cohort

Per Agent A's surgical foundational ingest, the registry currently anchors ten surgical robotics entities at distinct tier positions:

• Intuitive Surgical: da Vinci platform (1995 founding; gold standard of surgical robotics) + Ion (robotic bronchoscopy). 11,395 da Vinci systems + 1,041 Ion systems installed per SEC 10-Q. da Vinci 5 FDA-cleared March 2024. Maturity: production. The installed-base scale dwarfs all competitors combined.
• Medtronic Hugo: modular multi-arm surgical platform; corporate-scale entrant to the cohort; commercial outside US plus US clearances by indication. Teleoperated baseline.
• CMR Surgical Versius: UK-headquartered; modular small-form-factor surgical platform; commercial deployments across multiple geographies. Teleoperated baseline.
• Asensus/Karl Storz Senhance: Senhance platform now operating under the Karl Storz acquisition arrangement; commercial with FDA clearance. Teleoperated baseline.
• Stereotaxis Genesis: magnetic-navigation interventional platform (cardiac electrophysiology focus); distinct mechanism from arm-based surgical robotics; commercial with regulatory clearances.
• Distalmotion Dexter: Swiss-headquartered modular platform; commercial in Europe; FDA clearance progression in process. Teleoperated baseline.
• Moon Surgical Maestro: collaborative-robotic surgical assist platform; ScoPilot is the cohort's genuine shipped surgical AI standout, FDA-cleared with a Predetermined Change Control Plan (PCCP) that authorizes iterative model updates without re-submission. Commercial deployments anchored to specific hospital systems.
• Brain Navi NaoTrac: autonomous registration platform for cranial neurosurgery; clearance covers autonomous registration (the planning and alignment step), not autonomous tissue manipulation. Commercial in selected geographies.
• Johnson & Johnson Ottava: De Novo submission to FDA January 2026; FDA records list as "not authorized to be marketed." Maturity: research. The pre-market positioning despite J&J corporate scale is editorially substantial; the framework treats Ottava at research tier per FDA-clearance-as-gating-event discipline.
• Vicarious Surgical V1: pre-clearance platform; SPAC-era hype period preceded the current distressed pre-market state. Maturity: research. Framework treats Vicarious V1 at the same research tier as Ottava because both lack the verified gating event.

---

Editorial throughlines

Per DEPLOY's framework, three throughlines distinguish the surgical cohort from broader physical AI categories:

1. FDA clearance is the verified gating event. No clearance equals research tier regardless of demos, prototypes, or corporate parentage. J&J Ottava and Vicarious V1 demonstrate the discipline applied to corporate-scale and SPAC-era-hype respectively; both are research per the framework, not because the products are poor but because the regulatory gating event has not occurred. Cleared platforms (Intuitive, Medtronic, CMR, Asensus/Karl Storz, Stereotaxis, Distalmotion, Moon, Brain Navi) surface at verification tiers their installed base and clearance scope support.

2. The autonomy spectrum is bounded. The cohort's autonomy spectrum runs from teleoperated baseline (da Vinci, Hugo, Versius, Senhance, Dexter; surgeon directly controls instruments through console) through analytics AI on shipped hardware (Intuitive's analytics features layered onto teleoperated baseline) through narrow autonomous functions (Moon Surgical ScoPilot as the cohort's genuine shipped surgical AI standout, FDA-cleared with PCCP; Brain Navi NaoTrac for autonomous registration) to research demos on production hardware (autonomous suturing work on da Vinci, lab demonstrations not shipped as product). Autonomous tissue manipulation in clinical use does not yet exist as a shipped product.

3. Installed base vs competitive launch claims. Intuitive's 11,395 da Vinci + 1,041 Ion installed base per SEC 10-Q dwarfs the combined installed base of all competitor platforms. Trade-press coverage that frames new entrants as "challenging Intuitive's dominance" should be read against the installed-base differential: launch announcements and clearance milestones do not collapse the install-base gap. Per DEPLOY's framework, the gold-standard verified deployment all other surgical entrants are measured against is da Vinci.

---

Cross-category positioning

Surgical robotics sits at a distinct corner of the physical AI landscape:

• Distinct from humanoid robotics: surgical platforms are task-specific operating-room hardware, not general-purpose embodiment.
• Distinct from autonomous vehicles: surgical autonomy is bounded by FDA clearance scope and teleoperated baseline, not by closed-course safety driver depth.
• Distinct from AMRs and industrial robotics: surgical platforms operate inside the operating room under direct surgeon control, not autonomously inside warehouses or factories.
• Adjacent to interventional radiology robotics and dental robotics, both outside this specific cohort scope.

The cross-category placement matters because aggregator coverage often conflates surgical autonomy claims with broader physical AI autonomy claims; the regulatory framework differs, the customer base differs, and the verification questions differ.

---

Where to go for context

For the verified-at-scale anchor across the cohort, see what is Intuitive Surgical da Vinci. For the corporate-scale-doesn't-equal-verified exemplar, see what is Johnson & Johnson Ottava. For broader physical AI category context, see what is physical AI.

For the framework DEPLOY applies to verifying capability and deployment claims across operators, see how DEPLOY verifies capability claims. For methodology canonical references applicable to surgical robotics: the 4-way autonomy-boundary taxonomy (CANONICAL cross-cohort worked example: surgical cohort surfaces all 4 tiers: autonomous-execution + AI-augmented operator-controlled + replacement-robotics teleoperated + assistive co-pilot) + verified-vs-claimed at within-entity granularity (multi-procedure within-entity FDA clearance states) + the 9-tier source-quality rubric (FDA + SEC + reputable-press per-claim source classification).